Carisoprodol

psilodex.org/m/carisoprodol · data v2026.10.02

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Standard practice
Half-life: ~2 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: carisoprodol · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Muscle relaxant metabolized to meprobamate; sedative effects add with alcohol, benzodiazepines and opioids. The label reports abuse, dependence and withdrawal after abrupt cessation, and seizures, mostly in multiple-drug overdose. No psilocybin-specific data.

Human data with psilocybin: None known: no published human data with psilocybin
Common practice: Prolonged daily use carries withdrawal risk if stopped abruptly. Any change is the prescriber's decision.
Half-life: Carisoprodol ~2 h; active metabolite meprobamate ~10 h (FDA label, checked 2026-10-02)

Evidence types on this record

PrStandard practice; no psilocybin-specific data

02 Pharmacology relevant to psilocybin

3 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Any change to the dose is the prescriber’s decision. Sources [1]
Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

CARISOPRODOL tablets, for oral use CIV · FDA label (DailyMed) — additive sedation with CNS depressants; abuse, dependence and withdrawal; post-marketing seizures; CYP2C19 to meprobamate

Record history

v2026.10.02First published.
2026-10-02Last reviewed against its sources.

Report an error in this record →